Lord Lebedev Portrait

Lord Lebedev

Crossbench - Life peer

Became Member: 19th November 2020


Lord Lebedev is not a member of any APPGs
Lord Lebedev has no previous appointments


Division Voting information

During the current Parliament, Lord Lebedev has voted in 0 divisions, and never against the majority of their Party.
View All Lord Lebedev Division Votes

Debates during the 2024 Parliament

Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.

Sparring Partners
View All Sparring Partners
Legislation Debates
Lord Lebedev has not made any spoken contributions to legislative debate
View all Lord Lebedev's debates

Lords initiatives

These initiatives were driven by Lord Lebedev, and are more likely to reflect personal policy preferences.


Lord Lebedev has not introduced any legislation before Parliament

Lord Lebedev has not co-sponsored any Bills in the current parliamentary sitting


Latest 2 Written Questions

(View all written questions)
Written Questions can be tabled by MPs and Lords to request specific information information on the work, policy and activities of a Government Department
10th Dec 2024
To ask His Majesty's Government what assessment they have made of the potential neurodevelopmental impacts in children from prolonged screen time using mobile phones and social media, and how any such assessment informs public health guidance for families and schools.

In 2018, the United Kingdom’s Chief Medical Officer commissioned independent researchers at University College London to map published research on screen time, social media, and children and young people’s mental health. Their findings were published by the National Institute for Health Research.

On 7 February 2019, the Chief Medical Officer published a commentary on this research, alongside their advice for parents and carers, and their recommendations for other stakeholders. They determined that the evidence was insufficiently conclusive to support the Chief Medical Officer’s evidence-based guidelines on optimal amounts of screen use or online activities, such as social media use.

Baroness Merron
Parliamentary Under-Secretary (Department of Health and Social Care)
9th Dec 2024
To ask His Majesty's Government what assessment they have made of the evidence-base for the use of ketamine to treat trauma-related mental health conditions, and whether they plan to provide such treatments through NHS mental health services.

Ketamine does not have a marketing authorisation in the United Kingdom for use in the treatment of any mental health conditions. Esketamine nasal spray, an isomer of ketamine, is licensed for treatment-resistant depression that has not responded to at least two different antidepressants in the current moderate to severe depressive episode in adults, and for the treatment of adults with a moderate to severe episode of major depressive disorder, as acute short-term treatment for the rapid reduction of depressive symptoms, which, according to clinical judgement, constitutes a psychiatric emergency.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new, licenced medicines represent a clinically and cost-effective use of resources.

The NICE has been unable to recommend esketamine for treatment-resistant depression due to uncertainties in its clinical and cost-effectiveness. It is not therefore routinely funded by the NHS in England for any indication.

The NICE was unable to make recommendations on the use of esketamine nasal spray for the treatment of major depressive disorder because the marketing authorisation holder did not provide an evidence submission.

Baroness Merron
Parliamentary Under-Secretary (Department of Health and Social Care)